NCT01005654

Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms

RecruitingOBSERVATIONAL

Trial Details

Start: 2009-10-07

Enrollment target: 2,415 participants

Locations

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Contact

Kristine J Villaruelncieobinquiry@mail.nih.gov (240) 858-7033

Naris Nilubol, M.D.niluboln@mail.nih.gov (240) 760-6154

Other microbiome trials you might be interested in

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung CancerPhase 3Recruiting

Advanced Lung Non-Squamous Non-Small Cell CarcinomaMetastatic Lung Non-Squamous Non-Small Cell CarcinomaRecurrent Lung Non-Squamous Non-Small Cell CarcinomaStage IIIB Lung Cancer AJCC v8Stage IV Lung Cancer AJCC v8

This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatm…

Anchorage, United StatesEst. completion Dec 31, 2026

View Trial →

Enhanced Outpatient Symptom Management to Reduce Acute Care Visits Due to Chemotherapy-Related Adverse EventsRecruiting

Clinical Stage IV Esophageal Adenocarcinoma AJCC v8Clinical Stage IV Esophageal Squamous Cell Carcinoma AJCC v8

Apply or Learn More on ClinicalTrials.gov

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.